Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Why GoodRx (GDRX) Stock Is Up Today

August 27, 2025 at 12:32 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

GDRX Cover Image

What Happened?

Shares of healthcare tech company GoodRx (NASDAQ: GDRX) jumped 3.1% in the morning session after investor enthusiasm continued following its recent partnership with Danish pharmaceutical giant Novo Nordisk.

The positive momentum is a continuation of a significant rally that began on August 18, when the stock initially surged 37% upon the announcement of the deal. The partnership allows GoodRx to offer popular diabetes and weight-loss drugs Wegovy and Ozempic to self-paying customers at a substantial discount. Investors appear to remain optimistic that this agreement will provide a major customer and marketing boost for the prescription medication discount company, driving sustained interest in the stock.

After the initial pop the shares cooled down to $4.45, up 2.6% from previous close.

Is now the time to buy GoodRx? Access our full analysis report here, it’s free.

What Is The Market Telling Us

GoodRx’s shares are very volatile and have had 29 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was about 24 hours ago when the stock gained 3.7% on the news that investor enthusiasm continues following its recent partnership with Danish pharmaceutical giant Novo Nordisk.

GoodRx is down 2.4% since the beginning of the year, and at $4.45 per share, it is trading 48.2% below its 52-week high of $8.59 from August 2024. Investors who bought $1,000 worth of GoodRx’s shares at the IPO in September 2020 would now be looking at an investment worth $88.10.

Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article